Biotech | February 25, 2022
Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
he financing was significantly oversubscribed with high demand from both existing and new investors.
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Subscribe To Our Newsletter & Stay Updated
